Cargando…

Different rectal toxicity tolerance with and without simultaneous conventionally-fractionated pelvic lymph node treatment in patients receiving hypofractionated prostate radiotherapy

PURPOSE: To investigate added morbidity associated with the addition of pelvic elective nodal irradiation (ENI) to hypofractionated radiotherapy to the prostate. METHODS AND MATERIALS: Two-hundred twelve patients, treated with hypofractionated radiotherapy to the prostate between 2004 and 2011, met...

Descripción completa

Detalles Bibliográficos
Autores principales: McDonald, Andrew M, Baker, Christopher B, Popple, Richard A, Shekar, Kiran, Yang, Eddy S, Jacob, Rojymon, Cardan, Rex, Kim, Robert Y, Fiveash, John B
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4060093/
https://www.ncbi.nlm.nih.gov/pubmed/24893842
http://dx.doi.org/10.1186/1748-717X-9-129
_version_ 1782321323001774080
author McDonald, Andrew M
Baker, Christopher B
Popple, Richard A
Shekar, Kiran
Yang, Eddy S
Jacob, Rojymon
Cardan, Rex
Kim, Robert Y
Fiveash, John B
author_facet McDonald, Andrew M
Baker, Christopher B
Popple, Richard A
Shekar, Kiran
Yang, Eddy S
Jacob, Rojymon
Cardan, Rex
Kim, Robert Y
Fiveash, John B
author_sort McDonald, Andrew M
collection PubMed
description PURPOSE: To investigate added morbidity associated with the addition of pelvic elective nodal irradiation (ENI) to hypofractionated radiotherapy to the prostate. METHODS AND MATERIALS: Two-hundred twelve patients, treated with hypofractionated radiotherapy to the prostate between 2004 and 2011, met the inclusion criteria for the analysis. All patients received 70 Gy to the prostate delivered over 28 fractions and 103 (49%) received ENI consisting of 50.4 Gy to the pelvic lymphatics delivered simultaneously in 1.8 Gy fractions. The mean dose-volume histograms were compared between the two subgroups defined by use of ENI, and various dose-volume parameters were analyzed for effect on late lower gastrointestinal (GI) and genitourinary (GU) toxicity. RESULTS: Acute grade 2 lower GI toxicity occurred in 38 (37%) patients receiving ENI versus 19 (17%) in those who did not (p = 0.001). The Kaplan-Meier estimate of grade ≥ 2 lower GI toxicity at 3 years was 15.3% for patients receiving ENI versus 5.3% for those who did not (p = 0.026). Each rectal isodose volume was increased for patients receiving ENI up to 50 Gy (p ≤ 0.021 for each 5 Gy increment). Across all patients, the absolute V(70) of the rectum was the only predictor of late GI toxicity. When subgroups, defined by the use of ENI, were analyzed separately, rectal V(70) was only predictive of late GI toxicity for patients who received ENI. For patients receiving ENI, V(70) > 3 cc was associated with an increased risk of late GI events. CONCLUSIONS: Elective nodal irradiation increases the rates of acute and late GI toxicity when delivered simultaneously with hypofractioanted prostate radiotherapy. The use of ENI appears to sensitize the rectum to hot spots, therefore we recommend added caution to minimize the volume of rectum receiving 100% of the prescription dose in these patients.
format Online
Article
Text
id pubmed-4060093
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-40600932014-06-18 Different rectal toxicity tolerance with and without simultaneous conventionally-fractionated pelvic lymph node treatment in patients receiving hypofractionated prostate radiotherapy McDonald, Andrew M Baker, Christopher B Popple, Richard A Shekar, Kiran Yang, Eddy S Jacob, Rojymon Cardan, Rex Kim, Robert Y Fiveash, John B Radiat Oncol Research PURPOSE: To investigate added morbidity associated with the addition of pelvic elective nodal irradiation (ENI) to hypofractionated radiotherapy to the prostate. METHODS AND MATERIALS: Two-hundred twelve patients, treated with hypofractionated radiotherapy to the prostate between 2004 and 2011, met the inclusion criteria for the analysis. All patients received 70 Gy to the prostate delivered over 28 fractions and 103 (49%) received ENI consisting of 50.4 Gy to the pelvic lymphatics delivered simultaneously in 1.8 Gy fractions. The mean dose-volume histograms were compared between the two subgroups defined by use of ENI, and various dose-volume parameters were analyzed for effect on late lower gastrointestinal (GI) and genitourinary (GU) toxicity. RESULTS: Acute grade 2 lower GI toxicity occurred in 38 (37%) patients receiving ENI versus 19 (17%) in those who did not (p = 0.001). The Kaplan-Meier estimate of grade ≥ 2 lower GI toxicity at 3 years was 15.3% for patients receiving ENI versus 5.3% for those who did not (p = 0.026). Each rectal isodose volume was increased for patients receiving ENI up to 50 Gy (p ≤ 0.021 for each 5 Gy increment). Across all patients, the absolute V(70) of the rectum was the only predictor of late GI toxicity. When subgroups, defined by the use of ENI, were analyzed separately, rectal V(70) was only predictive of late GI toxicity for patients who received ENI. For patients receiving ENI, V(70) > 3 cc was associated with an increased risk of late GI events. CONCLUSIONS: Elective nodal irradiation increases the rates of acute and late GI toxicity when delivered simultaneously with hypofractioanted prostate radiotherapy. The use of ENI appears to sensitize the rectum to hot spots, therefore we recommend added caution to minimize the volume of rectum receiving 100% of the prescription dose in these patients. BioMed Central 2014-06-03 /pmc/articles/PMC4060093/ /pubmed/24893842 http://dx.doi.org/10.1186/1748-717X-9-129 Text en Copyright © 2014 McDonald et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
McDonald, Andrew M
Baker, Christopher B
Popple, Richard A
Shekar, Kiran
Yang, Eddy S
Jacob, Rojymon
Cardan, Rex
Kim, Robert Y
Fiveash, John B
Different rectal toxicity tolerance with and without simultaneous conventionally-fractionated pelvic lymph node treatment in patients receiving hypofractionated prostate radiotherapy
title Different rectal toxicity tolerance with and without simultaneous conventionally-fractionated pelvic lymph node treatment in patients receiving hypofractionated prostate radiotherapy
title_full Different rectal toxicity tolerance with and without simultaneous conventionally-fractionated pelvic lymph node treatment in patients receiving hypofractionated prostate radiotherapy
title_fullStr Different rectal toxicity tolerance with and without simultaneous conventionally-fractionated pelvic lymph node treatment in patients receiving hypofractionated prostate radiotherapy
title_full_unstemmed Different rectal toxicity tolerance with and without simultaneous conventionally-fractionated pelvic lymph node treatment in patients receiving hypofractionated prostate radiotherapy
title_short Different rectal toxicity tolerance with and without simultaneous conventionally-fractionated pelvic lymph node treatment in patients receiving hypofractionated prostate radiotherapy
title_sort different rectal toxicity tolerance with and without simultaneous conventionally-fractionated pelvic lymph node treatment in patients receiving hypofractionated prostate radiotherapy
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4060093/
https://www.ncbi.nlm.nih.gov/pubmed/24893842
http://dx.doi.org/10.1186/1748-717X-9-129
work_keys_str_mv AT mcdonaldandrewm differentrectaltoxicitytolerancewithandwithoutsimultaneousconventionallyfractionatedpelviclymphnodetreatmentinpatientsreceivinghypofractionatedprostateradiotherapy
AT bakerchristopherb differentrectaltoxicitytolerancewithandwithoutsimultaneousconventionallyfractionatedpelviclymphnodetreatmentinpatientsreceivinghypofractionatedprostateradiotherapy
AT popplericharda differentrectaltoxicitytolerancewithandwithoutsimultaneousconventionallyfractionatedpelviclymphnodetreatmentinpatientsreceivinghypofractionatedprostateradiotherapy
AT shekarkiran differentrectaltoxicitytolerancewithandwithoutsimultaneousconventionallyfractionatedpelviclymphnodetreatmentinpatientsreceivinghypofractionatedprostateradiotherapy
AT yangeddys differentrectaltoxicitytolerancewithandwithoutsimultaneousconventionallyfractionatedpelviclymphnodetreatmentinpatientsreceivinghypofractionatedprostateradiotherapy
AT jacobrojymon differentrectaltoxicitytolerancewithandwithoutsimultaneousconventionallyfractionatedpelviclymphnodetreatmentinpatientsreceivinghypofractionatedprostateradiotherapy
AT cardanrex differentrectaltoxicitytolerancewithandwithoutsimultaneousconventionallyfractionatedpelviclymphnodetreatmentinpatientsreceivinghypofractionatedprostateradiotherapy
AT kimroberty differentrectaltoxicitytolerancewithandwithoutsimultaneousconventionallyfractionatedpelviclymphnodetreatmentinpatientsreceivinghypofractionatedprostateradiotherapy
AT fiveashjohnb differentrectaltoxicitytolerancewithandwithoutsimultaneousconventionallyfractionatedpelviclymphnodetreatmentinpatientsreceivinghypofractionatedprostateradiotherapy